Category: Technology Licenses
Created On: 2022-04-28
Record Count: 14
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 372482
For the Licensor Trademarks, Licensor grants an exclusive, including with respect to Licensor except as to Licensorâ€™s performance of its obligations under this Agreement and conduct of Existing Clinical Trials, license, with the right to sublicense, to use the Licensor Trademarks solely in connection with Product in the Territory.
Transmucosal delivery devices with enhanced uptake;
Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces; and,
Transmucosal drug delivery for use in chronic pain relief.
Licensor controls certain patents and know-how relating to Product, and has initiated clinical studies with respect to the Product.
The Active Ingredient means buprenorphine. Buprenorphine is an opioid used to treat opioid use disorder, acute pain, and chronic pain.
Product means a drug product containing buprenorphine as its sole active ingredient (and not containing naloxone or any analog or derivative thereof and using Licensors BEMA Technology in any formulation and any dosage strength.
BEMA Technology means Licensorâ€™s proprietary BioErodible MucoAdhesive (BEMAÂ®) Drug Delivery Technology, a buccal soluble film consisting of a small bioerodible polymer film for application to the mucosal membranes (inner lining of the cheek).
IPSCIO Record ID: 372509
grants during the Term a non-exclusive, sub-licensable license under the Licensed Technology to, on a Licensed Product-by-Licensed Product basis and effective only with respect to the development of a Licensed Product for a particular indication following Governmental Approval of such Licensed Product for such indication, research and develop such Licensed Product in the Territory.
During the term of this Agreement, Licensor shall not sell any Licensed Product or any Competing Product with respect thereto for use in the Territory, nor grant any right or license to any Third Party with respect to the Licensed Product or any Competing Product in the Territory.
For the Trademarks, Licensor grants an exclusive, sub-licensable license to use the Marks during the Term solely in connection with the promotion, marketing, distribution, offer for sale, and sale of the Licensed Product in the Territory.
The Licensed Product means individually and collectively the BEMA-based product which contains fentanyl as it sole API, is currently the subject of Phase III clinical trials being conducted by Licensor, would, but for the licenses granted under this Agreement, infringe one or more claims of the Licensed Patent Rights, and does not contain naloxone as an additional ingredient. Fentanyl Product means any Licensed Product other than the Naloxone Product.
BEMA(TM) Fentanyl consists of a small, dissolvable, polymer delivery system, formulated with the opioid narcotic fentanyl, for application to the buccal (inner lining of cheek) membranes. BEMA(TM) Fentanyl has shown in Phase III clinical studies important patient advantages compared to competing products, especially fewer side effects.
BEMATM Fentanyl is a treatment for â€œbreakthroughâ€ cancer pain (i.e., episodes of severe pain which â€œbreak throughâ€ the medication used to control the persistent pain). BDSI believes there is a clear need and growing market for additional narcotic agents in alternative dosage forms to provide rapid pain relief. Fentanyl belongs to the group of medicines called narcotic analgesics, which are used to relieve pain
IPSCIO Record ID: 4069
The BEMAÂ® drug delivery technology is a buccal soluble film consisting of a small, BioErodible polymer film for application to the mucosal membranes (inner lining of cheek). BEMAÂ® films were designed to rapidly deliver a dose of drug across the mucous membranes for time sensitive conditions.
IPSCIO Record ID: 282856
Licensor hereby grants to Licensee a sole and exclusive, royalty-free license to use the Marks solely in connection with the use, promotion, marketing, distribution, offer for sale, and sale of the Products, on a Product-by-Product basis, in the Territory during the Royalty Term. Licensee may grant a sublicense to the Marks in accordance with this agreement.
Marks means â€œBEMAâ€ or any additional trademarks owned by Licensor with respect to the BEMA Technology, alone or accompanied by any logo or design and any non-English language equivalents in figure, sound or meaning, whether registered or not.
Fentanyl Product means the first Product containing Fentanyl, used for the treatment of pain and sold in a Commercial Sale.
BEMA Patent Rights means all Patent Rights in the Territory related to the patents and patent applications listed, claiming BEMA or any Improvement, or which are necessary or appropriate to develop, manufacture and commercialize Products in the Territory, and that are under the Control of Licensor as of the Effective Date or that come under Licensors Control during the Term.
5,800,832 – Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
6,159,498 – Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces
BEMA Technology means the BEMA Patent Rights and the BEMA Know How.
The BEMA(TM) technology allows for the delivery of drugs across the buccal (i.e., mouth) mucosa that provides a rapid onset of therapeutic effect and a competitive advantage in such areas as pain relief and sedation.
IPSCIO Record ID: 289191
Product means the Licensed Product, Placebos, and Demonstration Samples.
The Drug Product is BEMA rM Fentanyl, Bucco/ Soluble Film
BEMA means the proprietary bioerodible, mucoadhesive multi-layer polymer film technology Controlled by Licensor.
The Field means the treatment of breakthrough cancer pain in patients tolerant to opioids, the Initial Indication, and, following Governmental Approval in the Territory of the Licensed Product for the Initial Indication, any additional human therapeutic indications for which Governmental Approval is obtained.
IPSCIO Record ID: 212269
Licensee will be responsible for the manufacturing, distribution, marketing and sales of ONSOLIS in the U.S.
IPSCIO Record ID: 203466
Licensor grants an exclusive, non-transferable, except in accordance with a permitted assignment of this Agreement, license in the Field to use Licensors trademark.
The Licensors trademark is ORADISC.
IPSCIO Record ID: 256300
The Parties wish to cooperate in the exclusive manufacturing of the Products and Placebos in the Territory.
The Active Principle shall mean Fentanyl.
The Product shall mean Licensees transmucosal oral system containing Active Principle based on the Design of Licensee Technology.
Licensee has bioerodable mucoadhesive transmucosal technology.
Licensor has technology and process for oral film form products and/or pharmaceutical preparations in general, their use, process development, including without limitation the mass preparation, coating, drying and compiling thereof, and, manufacturing, packaging, and labeling.
U.S. Patents Nos. 5,948,430, 6,177,096 and 6,284,264
The Licensee lead BEMAâ„¢ product under development is BEMAâ„¢ Fentanyl, a treatment for breakthrough cancer pain.
IPSCIO Record ID: 319229
Intellectual Property includes but not limited to the US Patent Nos. 8,278,277. This covers lipophilic derivatives of hydrophilic drugs comprising a hydrophilic drug and a cleavable linker as well as methods of treatment using these compositions. In particular the patents relate to compositions of a lipophilic derivative of the hydrophilic neuropeptide Leucine -Enkephalin and an amphiphile compound, where the derivative includes a lipophilic linker attached to the side chain oxygen of the tyrosine in the Leucine -Enkephalin, and where the amphiphile compound is quaternary palmitoyl glycol chitosan (GCPQ).
8,278,277 – Delivery of hydrophilic drugs
Licensor is a leader in pharmaceutical nanotechnology. The nanomedicines know-how and proprietary technology platforms provide drug delivery solutions for poorly water soluble drugs, nucleic acids and peptides.
IPSCIO Record ID: 324674
In addition, the Licensor hereby grants to Licensee a non-exclusive right under Additional Know-How to make, have made, use, offer to sell, sell and import Products in the Therapeutic Areas, with the right to grant sublicenses, in the Territory.
Products means any and all pharmaceutical or veterinary products, combinations and compositions which contain one or more of the compounds
Tizandine, excluding Combination Products.
IPSCIO Record ID: 233472
The patents relate to Delivery of Opioids through an Inhalation Route.
The technology, the Staccato system, vaporizes excipient-free drugs to form condensation aerosols that, when inhaled, allows for rapid systemic drug delivery. Because of the particle size of the aerosol, the drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous, or IV, administration but with greater ease, patient comfort and convenience.
IPSCIO Record ID: 203511
Licensor also grants access to and a right of cross-reference, solely to exercise its rights pursuant to the foregoing license, to the following, in each case to the extent Controlled by Licensor and its Affiliates all Development Data in existence as of the Effective Date; all data related to the formulation or composition of the Product in existence as of or after the Effective Date; and to the extent useful for Licensee or its Sublicensees to develop, make, have made, use, sell, offer to sell, import, export, register, market and promote the Product in the Licensed Field in the Licensed Territory in accordance with Licenseeâ€™s rights under this Agreement, all Preclinical, Non-Clinical and Clinical data, including without limitation pharmacological, pharmacokinetic and toxicological data, [generated with respect to Chronogesic useful in connection with seeking Regulatory Approval for Chronogesic (Chronogesic Data) from trials commenced prior to the Effective Date.
The Product means a transdermal patch for human use using the Licensor Technology containing sufentanil (including all salts thereof) and having a duration of application of (14] days or less, including all dosage strengths thereof and line extensions thereof, and including al] improvements thereto, [together with any adhesive overlay intended for use with such patch.] The term Product includes [any Authorized Generic Product] except as expressly provided herein.
The sufentanil patch, which is in early-stage clinical development employs Licensor's proprietary TRANSDUR(TM) drug-adhesive matrix formulation and is intended to provide relief of moderate-to-severe chronic pain for up to seven (7) days. The product's weeklong duration combined with its reduced size (about 20% of the size of the on-market transdermal fentanyl patches but with a therapeutically equivalent dose) may offer improved patient convenience and compliance.'
Sufentanil is a synthetic opioid analgesic drug approximately 5 to 10 times more potent than its parent drug, fentanyl, and 500 times as potent as morphine.
United States Provisional Patent Application Number 60/621,123 for 'Transdermal Delivery Systems
United States Utility Patent Application Number 10/922,239for 'Implantable Devices and Methods for Treatment of Pain by Delivery of Fentanyl and Fentanyl Congeners
United States Utility Patent Application Number 11/044,521 for 'Devices and Methods for Pain Management'
IPSCIO Record ID: 368511
Subsequent Platform Technology. with respect to the Subsequent Product, shall mean and include that certain technology that is the subject matter of US Patent Application No. 60/783,181 for Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes, and any improvements thereto whether patentable or not.
Compound shall mean morphine sulfate and/or morphine polystyrene.
Initial Product shall mean the pharmaceutical formulation developed under this Agreement that is demonstrated to have Bioequivalence to KADIANÂ® Referenced Product
KADIANÂ® NT shall mean the abuse deterrent form of the KADIANÂ® Reference Product which is presently the subject of Phase Ill trials being performed by or on behalf of Licensee.
Subsequent Product shall mean the pharmaceutical formulation developed under this Agreement that is demonstrated to have Bioequivalence to KADIANÂ® Referenced Product, or as to which Licensee elects to proceed hereunder without Bioequivalence) containing the Compound as its single active ingredient in a Subsequent extended-release suspension formulation with a concentration of at least 30 mg/15 ml using Licensor Subsequent Platform Technology, at one specific strength that is developed as part of the Development and Regulatory Program. In the event that the Subsequent Product is not Bioequivalent to the KADIANÂ® Referenced Product, Licensee shall have the option, but not the obligation, to proceed with the Development and Regulatory Program as if the Subsequent Product achieved Bioequivalence.
Kadian (morphine sulfate) is a narcotic pain reliever used to treat moderate to severe pain.
Licensee will gain access to Licensor's LiquiXR(TM) technology, a novel and proprietary drug delivery platform for sustained release products in liquid form. The company plans to use this technology to develop an oral liquid product complementary to the company's KADIANÂ® solid dose product line.
IPSCIO Record ID: 280823
Compound means any proprietary compound, its derivatives, metabolites, and intermediates, owned or controlled by Licensee, that Licensee provides pursuant to any Research Plan or any Exploratory Development Program Plan.
Area means research or development with respect to delivery systems for Licensee Compounds.
Licensor Technology means all technology, technical information, know-how, expertise and trade secrets owned or controlled by Licensor as of the Effective Date of this Agreement, that relates to and/or is useful in developing the Atrigel(R) System, the bioerodible mucoadhesive disc (BEMA(TM)) system, the mucoadhesive gel (MCA(TM)) system, the solvent microparticulate (SMP(TM)) system and/or other drug delivery technology owned or controlled by Licensor.
ATRIGEL(R) System means the biodegradable, polymeric drug delivery system in all embodiments claimed in the Licensor Patent Rights.